WHOOP says its most engaged members are 65 or older. Medicare wants to see what changes for patients.

Will Ahmed described WHOOP’s shift from athletic recovery to chronic care. Michael Phelps explained what happened when his coaches could see the data.

Author
HDM Staff
Save
Share
Will Ahmed, Michael Phelps and Lynne O’Keefe share the HLTH Main Stage
Will Ahmed, Michael Phelps and moderator Lynne O’Keefe discuss health tracking in Las Vegas. Photo credit: HLTH USA 2026.

    WHOOP’s most engaged members are 65 or older, founder and CEO Will Ahmed said in Las Vegas, a finding he said helped make the case for entering Medicare’s experiment in technology-supported chronic care. The company built its early reputation with athletes like Michael Phelps, who used its measurements to help decide when to push and when to ease up. Now a WHOOP affiliate has to show what happens when it uses data from a wearable as part of care for eligible patients with conditions such as high blood pressure.

    Ahmed discussed that shift with Phelps in a Nov. 17 Main Stage conversation moderated by Lynne O’Keefe, founder and managing partner of Define Ventures. Ahmed said WHOOP was seeing “the highest engagement coming from 65 plus.” He offered no breakdown of the engagement measure, sample sizes or how long members in each age group had used the product. The observation describes WHOOP’s existing members. It tells healthcare organizations something about who may be willing to use the technology and raises a separate question about what that use accomplishes.

    A Medicare test of what the data changes

    The Centers for Medicare & Medicaid Services lists WHOOP Physician Services in the early cardio-kidney-metabolic track of its ACCESS Model. WHOOP says its Connected Care program is available to eligible people with Original Medicare and a qualifying condition. The model ties payments to care and specified outcomes, including measures such as blood pressure, cholesterol, blood sugar and weight where applicable. The program applies to eligible beneficiaries enrolled with a participating organization. Ahmed’s description of a device at no cost referred to WHOOP’s participation in that program, which has its own eligibility and enrollment process.

    That creates a different standard from the one a fitness company can use to judge a new feature. How often someone opens an app or how long they wear a device may help explain whether a program can collect useful information. Those activities do not determine whether someone’s blood pressure improved or stayed under control. An evaluation also has to account for the care around the device, including what a clinician does when data point to a problem and whether the patient gets follow-up.

    Ahmed suggested that WHOOP could combine wearable trends, lab results, medical records and what a person tells its software into a short account for a clinician. He asked how to reduce all that information to “one, two, or three questions” a doctor might want answered before an appointment. WHOOP’s product documentation says members can connect electronic health records through HealthEx. A clinician would still need to know where the data came from, over what period they were collected and which observations are reliable enough to support a decision.

    O’Keefe asked whether continuous tracking changes the need for office visits. Ahmed argued that a trend across many days can provide information a single appointment cannot. He also envisioned software that could eventually flag a serious problem and arrange a visit. The discussion supplied no performance evidence for that scenario. The functions a wearable already offers have different purposes and standards. Ahmed cited cleared heart rhythm features and separately described the company’s blood pressure insights as a wellness feature. A stream of sensor estimates and an office evaluation can contribute different information to the same patient’s care.

    Phelps used the numbers with a coach

    Phelps described what using the device looked like when his job was to race in “hundredths of a second.” His coach and trainer could see his data and adjust what he did in training. If his recovery appeared low, they had a reason to reconsider how hard to work that day. Phelps talked about knowing his own patterns and having people around who understood his goals. The data entered an established relationship in which someone could interpret it, ask questions and change the plan.

    He recalled noticing several measurements outside his usual range when he felt ill after a trip. A COVID test subsequently came back positive, he said. The episode illustrated how a change from a familiar baseline can draw someone’s attention. It offered no evidence that a wearable can identify the cause of illness. A person may sleep poorly, travel or feel unwell for many reasons, and the next decision can depend on symptoms and other evidence that never show up on the device.

    Phelps said the aim has changed since his competitive career. He still pays attention to sleep and recovery, but described easing up so he has energy for family and work. When O’Keefe asked about his mental health, he described a group of friends who make themselves available to talk when someone is struggling. He prefers a video call when someone needs support. “I want to see your face,” he said. In his account, the important information was something another person could pick up by listening and seeing how a friend was doing.

    Where a partnership still needs evidence

    O’Keefe also asked about the company’s involvement with Novo Nordisk’s redesigned Novocare program, which announced third-party resources including WHOOP that day. Ahmed said the wearable could help users compare patterns in sleep or activity before and during treatment. The companies’ announcement identified WHOOP as a partner resource. The discussion did not establish that using the wearable improves treatment results for people taking a GLP-1 medicine. A healthcare team would need to distinguish any effect of the drug, other support and changes in a patient’s routines.

    The clearest evidence to watch is in the Medicare program. The question is how many eligible patients get enrolled and receive follow-up, and whether they reach the measures the program uses to judge care. Some will already be comfortable wearing a device. Others may need help getting started or may want to share only certain data. A program that works for existing enthusiasts will have more to prove when it serves those patients.

    Phelps’s example helps show why the distinction matters. A coach could look at his numbers and change one workout. In a chronic care program, the useful next step might be a conversation, a repeat measurement or a review of the patient’s treatment plan. Knowing who takes that step, and whether it helps the patient, will tell healthcare organizations more than knowing how long someone kept the wearable on.